Can-Fite BioPharma (CANF) Net Cash Flow (2013)
Can-Fite BioPharma's (CANF) quarterly Net Cash Flow came in at -$1.7 million in Q3 2013.
Can-Fite BioPharma (CANF) Net Cash Flow (2013) Analysis & Trends
Can-Fite BioPharma (CANF) has 1 years of Net Cash Flow data on file, last reported at -$1.7 million in Q3 2013.
- Quarterly Net Cash Flow changed N/A year-over-year to -$1.7 million in Q3 2013, while the trailing twelve-month figure through Jun 2014 was -$1.7 million (changed N/A YoY) and the FY2025 annual result came in at $693000.0, up 21.79% from the prior year.
- Net Cash Flow was little changed at -$1.7 million in Q3 2013.
- In the past five years, Net Cash Flow ranged from a high of -$1.7 million in Q3 2013 to a low of -$1.7 million in Q3 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | Can-Fite BioPharma | 2.82 Mn | -8.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2013 | -1.70 Mn |
| Sep 30, 2013 | -1.70 Mn |